The Pharmaletter

One To Watch

Semnur Pharmaceuticals

A clinical-late stage specialty pharma company developing and commercializing novel non-opioid pain therapies.

Semnur’s lead program, SP-102 (SEMDEXA™), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica.

It is a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain.

Want to Update your Company's Profile?


Latest Semnur Pharmaceuticals News

More Semnur Pharmaceuticals news >